 |
 |
Date Announced: 16 Feb 2018
Treatment for Retinitis Pigmentosa in 62-year-old patient.
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind patients, today announced market entry into Singapore, with the first patient implanted with the Company’s Argus® II Retinal Prosthesis System (“Argus II”). The implantation was facilitated by the Company’s exclusive distribution partner in Singapore, Mandarin Opto-Medic Co Pte Ltd.
“We are delighted to have completed our first Argus II surgery in Singapore, in collaboration with another leading international eye center. This further increases the global reach of the Argus II to individuals with Retinitis Pigmentosa (RP). The growing adoption of Argus II continues to validate its benefit to patients by offering them some functional vision. We look forward to ongoing growth in Singapore and other markets,” said Will McGuire, President and Chief Executive Officer of Second Sight.
The implantation was performed at the Singapore National Eye Center (SNEC) on January 18, 2018 in a 62-year-old male patient with retinal degeneration by Dr. Edmund Wong and Dr. Laurence Lim. Professor Emin Özmert from the University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey acted as a supporting surgeon.
Source: Second Sight
E-mail: via web site
Web Site: www.secondsight.com
| © 2024 SPIE Europe |
|
